Background: Studies on the mechanisms of lymphangiogenesis and lymphatic metastasis in lung squamous cell carcinoma (LUSC) are rare. Our previous studies analyzed the data from TCGA and found that the high expression of VASH2 in LUSC patients was significantly related with their poor prognosis. VASH2 has been reported as a pro-angiogenic factor in many kinds of tumors, however, its effects on the occurrence and progression of LUSC has not been illuminated yet. Method: The expression of VASH2 in LUSC amples was detected by quantitative PCR and immunohistochemistry. We analyzed the correlation between the expression of VASH2 and the survival and prognosis of patients in LUSC amples. Then we constructed a stable LUSC cell line H520
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VASH2 hi with high expression of VASH2, and investigated its regulation on cell proliferation, apoptosis, migration, invasion and lymph node metastasis in vitro, and its role in promoting tumor genesis and lymph node metastasis in vivo. We also applied VEGF-D and Snail inhibitors in vitro and in vivo to investigate their therapeutic effects on lymph node metastasis. Results: We observed that the high expression of vash2 was significantly associated with lymph node metastasis in patients with LUSC. In LUSC cell lines with high expression of VASH2, the ability of proliferation, invasion and metastasis was enhanced and lymphangiogenesis was promoted. At the same time, the expression of lymphangiogenesis factor VEGF-D and Snail were upregulated. When Snail was knockdown, the ability of invasion and metastasis was weakened, the expression of VEGF-D was down-regulated and lymphangiogenesis was decreased in H520 Background: At present, limited data exist on the spectrum of resistance mechanisms in ROS1-positive lung cancer. The Hippo-YAP pathway has been recently implicated in the acquisition of drug resistance in anti-cancer therapy, Yes-associated protein (YAP) is a main mediator of the Hippo pathway, but no data are available about Hippo-YAP pathway in ROS1-positive lung cancer. In this study, we evaluated the expression of YAP in non-small-cell lung carcinoma (NSCLC) tissues, we also investigated the role of YAP in primary and crizotinib-resistant cell lines. Method: Immunohistochemical (IHC) staining of YAP and epithelial-to-mesenchymal transition (EMT) proteins was performed on tissue sections from 200 NSCLCs. Correlations between the expression of the above proteins and clinicopathologic features and prognostic significance were analyzed. Crizotinib -resistant cells (HCC78CR) were established using crizotinib -naïve HCC78 cells. (SLC34A2-ROS1 fusion). Results: Our study found the increased expression of YAP and epithelial-to-mesenchymal transition (EMT) proteins in ROS1-positive lung cancer tissues, and there was a correlation between them. In ROS1-positive adenocarcimoma, high nuclear YAP expression was associated with larger tumor size (p ¼ 0.002), vascular invasion (p < 0.001), lymphatic invasion (p < 0.001), perineural invasion (p ¼ 0.016) and advanced pathologic stage (p < 0.001). Cytology experiments demonstrated that YAP and EMT related genes and proteins (ZEB1, SNAIL, SLUG, VIMENTIN) were highly expressed in ROS1-positive crizotinib-resistant lung cancer cells. After blocking of YAP, the expression of EMT pathway genes (Snail, Zeb1, Vimentin) and proteins were decreased, YAP re-sensitized the cells to inhibiting proliferation by crizotinib. Conclusion: Based on these findings, we proposed a novel hypothesis that: YAP plays an important role in the drug resistance of ROS1-positive lung cancer and YAP acts as a transcriptional regulator by binding to transcription factors of EMT pathways. Keywords: YAP pathway, ROS1-positive lung cancer, Epithelial-tomesenchymal transition, crizotinib resistance
P076 A Lung Adenocarcinoma with Concomitant EGFR And De Novo MET Amplification Response Well to Combination of TKI And Bevacizumab
Background: Patients with NSCLC who are carrying concomitant de novo EGFR and MET amplification were commonly reported to have poor response to therapy. Here, we presented a case of a patient harboring concomitant de novo MET and EGFR, who obtained favorable response to combinatorial therapy of TKI and bevacizumab. Method: We presented a lung adenocarcinoma patient harboring dual EGFR-MET alterations, and evaluated his response to combinatorial therapy of TKI and bevacizumab. In vitro experiments were performed in HCC827(EGFR-19del) and HCC827-GR (EGFR-19del+MET amplification) cells to validate the effect of bevacizumab on MET pathway. Results: A 44-year-old male stage IV lung adenocarcinoma with left lung tumor was detected harboring of EGFR-19del and MET amplification using PCR and FISH. The patient was treated with erlotinib+beva-cizumab and achieved partial response (PR) with a PFS with 13 months. After PD, NGS performed on both tissue and plasma biopsies revealed that the patients obtained first-generation resistant mutation EGFR-T790M, concomitant with EGFR-19del. The patient was treated with osimertinib+bevacizumab and achieved PR. He developed PD again with a PFS of 10.2 months, and repeated biopsies sequencing identified concomitant EGFR-19del and MET amplification. Then, the patient was treated with crizotinib+bevacizumab and the best curative effect was stable disease. Four months later, he developed PD and the third biopsy still revealed positive EGFR-19del and MET amplification. The patient received osimertinib+crizotinib+bevacizumab and he achieved PR one month after treatment initiation. He is still under the treatment and the PFS is more than eight months. In vitro data revealed that, under gefitinib treatment, cell viability was higher in HCC827(EGFR-19del) than HCC827-GR (EGFR-19del+METamp). However, the patient harboring dual EGFR-MET alterations in this study obtained a PFS of 13 months to erlotinib, similar with patients with EGFR-19del only (mPFS was 13 months to erlotinib as reported), suggesting the efficacious treatment of EGFR-TKI and bevacizumab than TKI alone. We observed that VEGFR-2 was expressed at relatively high levels in HCC827-GR than other cell line without METamp, and VEGF pathway inhibition by bevacizumab resulted in decreased phospho-c-Met in HCC827-GR cell lines. This result provided in vitro evidence that bevacizumab can reduce MET pathway activation. Conclusion: This study provided basic knowledge and evidence for patients harboring concomitant EGFR and de novo MET amplification who may obtain favorable response to combinatorial
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